You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
永勝醫療(01612.HK)全年純利減少62.8%至1152.5萬港元
格隆匯 03-20 17:35

格隆匯3月20日丨永勝醫療(01612.HK)發佈全年業績,截至2019年12月31日止年度,公司實現收入5.022億港元,同比增長2.9%;公司擁有人應占溢利1152.5萬港元,同比減少62.8%,若不計入投資及商譽減值,2019年基礎盈利為2110萬港元;基本每股盈利1.81港仙;擬派末期股息每股1.1港仙。

公告表示,在OBM分部銷售額較高的推動下,集團於2019年的總收入增加2.9%。來自美國市場的收入維持相對穩定至3.194億港元,而來自中國市場的收入增加23.6%。OEM分部及OBM分部分別為集團的總收入貢獻74.9%(2018年:79.9%)及25.1%(2018年:20.1%)。

此外,OEM分部的收入為3.764億港元,減少3.4%,佔集團總收入的74.9%(2018年:79.9%)。該減少主要由於若干原材料供應商的產品出現品質問題而導致該等原材料供應暫時短缺,影響到成像一次性產品於2019年下半年的生產。然而,呼吸產品及骨科支護復康器具的收入貢獻較高,能夠部份抵銷成像一次性產品及其他產品的收入減少。儘管成像一次性產品產量有所減少,OEM分部毛利率仍維持穩定於30.1%(2018年:30.4%)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account